RecruitingPhase 1NCT05103683
First in Human Study of TORL-1-23 in Participants With Advanced Cancer
Studying Malignant epithelial tumor of ovary
Last synced from ClinicalTrials.gov
ℹ
Clinical trial records are synced from ClinicalTrials.gov through automated extraction.
Report missing dataKey facts
- Sponsor
- TORL Biotherapeutics, LLC
- Principal Investigator
- Nora Ku, MD, MDTORL Biotherapeutics, LLC
- Intervention
- TORL-1-23(drug)
- Enrollment
- 90 enrolled
- Eligibility
- 18 years · All sexes
- Timeline
- 2021 – 2026
Study locations (14)
- Providence Medical Foundation, Fullerton, California, United States
- UCLA - JCCC Clinical Research Unit, Los Angeles, California, United States
- University of Kentucky Medical Center, Lexington, Kentucky, United States
- University of Minnesota, Minneapolis, Minnesota, United States
- Mayo Clinic in Rochester, Rochester, Minnesota, United States
- Memorial Sloan Kettering Cancer Center, New York, New York, United States
- Cleveland Clinic, Cleveland, Ohio, United States
- Sarah Cannon Research Institute Texas Oncology, Tyler, Texas, United States
- Virginia Cancer Specialists, Fairfax, Virginia, United States
- St. Vincent's Hospital, The Catholic University of Korea, Suwon, Gyeonggi-do, South Korea
- Seoul National University Hospital, Seoul, South Korea
- Severance Hospital, Seoul, South Korea
- Asan Medical Center, Seoul, South Korea
- Samsung Medical Center, Seoul, South Korea
Collaborators
Translational Research in Oncology
Primary source
Recruitment status, site addresses, contacts, and full eligibility criteria can change between syncs. Always verify with the trial team before planning travel or treatment.
Open NCT05103683 on ClinicalTrials.govOther trials for Malignant epithelial tumor of ovary
Additional recruiting or active studies for the same condition.
- RECRUITINGNCT07508306Patent Blue SLN in Early Ovarian Cancer Prospective Study (FIGO I-II) Evaluating Patent Blue SLN Mapping. Injection Into IP/UO Ligaments in Situ. Goals: Assess Feasibility and Accuracy vs Standard Lymphadenectomy to Minimize Surgical MorbidityFaculty of Medicine of Tunis
- RECRUITINGPHASE1NCT07524322Study of RGT-490 in Patients With PIK3CA-Mutated Advanced Solid TumorsRegor Pharmaceuticals Inc.
- RECRUITINGPHASE1NCT06366490Safety and Immunogenicity of Innocell Autologous Cellular Immunotherapy for Recurrent Epithelial Ovarian CancerPhotonPharma, Inc.
- RECRUITINGPHASE1NCT07402915Drug-drug Interaction Study With AZD5335 and Itraconazole in Participants With Ovarian, Primary Peritoneal, or Fallopian Tube CancerAstraZeneca
- RECRUITINGPHASE2NCT07158021Leuprolide and Goserelin for Ovarian Function Suppression in Pre- or Peri-menopausal Women With Breast Cancer, OFS TrialUniversity of Michigan Rogel Cancer Center
- RECRUITINGNANCT07280312Ultrasound Microvessel Imaging for the Evaluation of Ovarian and Adnexal LesionsMayo Clinic
- RECRUITINGPHASE2NCT06971744Autophagy Maintenance (AUTOMAIN)Medical University of South Carolina
- RECRUITINGPHASE3NCT07544030A Randomized Controlled Trial Evaluating the Feasibility and Preliminary Efficacy of Pressurized Intraperitoneal Aerosol Chemotherapy (PIPAC) in Advanced Epithelial Ovarian Cancertongweihua